Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | F13A1 | P00488 | 1/20 | 0.50 |
| ▸ | TGM1 | P22735 | 1/20 | 0.50 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11179193 | 0.81 | TGM2 (0.53) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL14203835 | 0.77 | TGM2 (0.52) | TGM2LMNAF13A1TGM1TGM3 | |
| Acrylamide SCHEMBL28343508 | 0.75 | TGM2 (0.47) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL9865216 | 0.75 | TGM2 (0.68) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL15348740 | 0.74 | LMNA (0.45) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL16095513 | 0.74 | TGM2 (0.54) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL2723363 | 0.74 | TGM2 (0.42) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL20379487 | 0.71 | TGM2 (0.50) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL8369413 | 0.70 | HTT (0.65) | LMNAKMT2AHTTALDH1A1GPR35 | |
| SCHEMBL4733404 | 0.69 | TGM2 (0.41) | TGM2LMNAF13A1TGM1TGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | MAPK1, NOS1, NOS2 | TGM2 3571/4885LMNA 2404/4885F13A1 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.